EXAS vs. ZBH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and ZBH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXAS | ZBH |
|---|---|---|
| Company Name | Exact Sciences Corporation | Zimmer Biomet Holdings, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 12.87 billion USD | 17.77 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | February 1, 2001 | July 25, 2001 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXAS and ZBH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | ZBH |
|---|---|---|
| 5-Day Price Return | 0.68% | 1.33% |
| 13-Week Price Return | 47.00% | -12.50% |
| 26-Week Price Return | 24.89% | -7.78% |
| 52-Week Price Return | 32.13% | -18.24% |
| Month-to-Date Return | 3.62% | -10.59% |
| Year-to-Date Return | 19.29% | -14.88% |
| 10-Day Avg. Volume | 3.67M | 3.26M |
| 3-Month Avg. Volume | 2.86M | 1.67M |
| 3-Month Volatility | 29.23% | 36.54% |
| Beta | 1.43 | 0.63 |
Profitability
Return on Equity (TTM)
EXAS
-40.39%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
EXAS has a negative Return on Equity of -40.39%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
ZBH
6.42%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
ZBH’s Return on Equity of 6.42% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXAS
-32.01%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
EXAS has a negative Net Profit Margin of -32.01%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
ZBH
10.05%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
ZBH’s Net Profit Margin of 10.05% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
EXAS
-32.45%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
EXAS has a negative Operating Profit Margin of -32.45%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
ZBH
16.63%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
ZBH’s Operating Profit Margin of 16.63% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EXAS | ZBH |
|---|---|---|
| Return on Equity (TTM) | -40.39% | 6.42% |
| Return on Assets (TTM) | -16.91% | 3.58% |
| Net Profit Margin (TTM) | -32.01% | 10.05% |
| Operating Profit Margin (TTM) | -32.45% | 16.63% |
| Gross Profit Margin (TTM) | 67.37% | 71.44% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXAS’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ZBH
2.43
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
ZBH’s Current Ratio of 2.43 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.94
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
ZBH
0.64
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
ZBH’s Debt-to-Equity Ratio of 0.64 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ZBH
5.76
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
ZBH’s Interest Coverage Ratio of 5.76 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXAS | ZBH |
|---|---|---|
| Current Ratio (MRQ) | 2.72 | 2.43 |
| Quick Ratio (MRQ) | 2.24 | 1.20 |
| Debt-to-Equity Ratio (MRQ) | 0.94 | 0.64 |
| Interest Coverage Ratio (TTM) | -15.18 | 5.76 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ZBH
1.09%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Yield of 1.09% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ZBH
23.70%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
ZBH’s Dividend Payout Ratio of 23.70% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | EXAS | ZBH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.09% |
| Dividend Payout Ratio (TTM) | 0.00% | 23.70% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for EXAS is currently unavailable.
ZBH
21.79
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
In the lower quartile for the Health Care Equipment & Supplies industry, ZBH’s P/E Ratio of 21.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EXAS
4.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
ZBH
2.19
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
ZBH’s P/S Ratio of 2.19 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXAS
4.14
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXAS’s P/B Ratio of 4.14 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
ZBH
1.53
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
ZBH’s P/B Ratio of 1.53 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EXAS | ZBH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 21.79 |
| Price-to-Sales Ratio (TTM) | 4.12 | 2.19 |
| Price-to-Book Ratio (MRQ) | 4.14 | 1.53 |
| Price-to-Free Cash Flow Ratio (TTM) | 51.33 | 15.51 |